A Multicenter Phase II Evaluation Of ONTAK (DENILEUKINDIFTITOX) In Patients With Low Or Intermediate Grade-B-Cell Non-Hodgkin's Lymphoma Who Have Been Treated Previously With A Monoclonal Antibody Or Who Are Not Candidates For Monoclonal Antibody Therapy
OBJECTIVES: I. Determine the efficacy of denileukin diftitox in patients with stages I-IV
low- or intermediate-grade B-cell non-Hodgkin's lymphoma. II. Determine the safety of this
drug in these patients.
OUTLINE: This is a multicenter study. Patients receive denileukin diftitox IV over 30-60
minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or
unacceptable toxicity. Patients may receive up to 2 additional courses after achieving
complete response. Patients are followed every 3 months until they have progressed or for 2
years from date of termination.
PROJECTED ACCRUAL: A total of 58 patients (29 with low-grade non-Hodgkin's lymphoma (NHL)
and 29 with intermediate-grade NHL) will be accrued for this study within 12 months. The
study may be stopped after accrual of 20 patients (10 with low-grade NHL and 10 with
intermediate-grade NHL) if observed response rate is less than 1 in 10 for each stratum.
Primary Purpose: Treatment
United States: Federal Government
|Cancer and Blood Institute of the Desert||Rancho Mirage, California 92270|
|Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group||Memphis, Tennessee 38119|
|Missouri Cancer Care, P.C.||St. Charles, Missouri 63301|
|Nassau Hematology/Oncology PC||Lake Success, New York 11042|
|ION/Pharmatech Network||Pomona, California 91767|
|Coastal Cancer Center||Myrtle Beach, South Carolina 29572|